Pulmonary delivery of insulin

Current Medical Research and Opinion

Volumn 22, Issue SUPPL. 3, 2006, Pages

  Patton, John ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

Diabetes mellitus, type 1; Diabetes mellitus, type 2; Inhaled insulin; Inhalers; Insulin; Pulmonary delivery

Indexed keywords

INSULIN;

CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUSTRY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG FUNCTION; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TREATMENT OUTCOME;

EID: 33750573124     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X132695     Document Type: Review

References (44)

1. Banting FG, Best CH, Collip JB, et al. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922;12:141-6
2. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulponylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
4. Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239-46
5. Hamilton JG. Needle phobia: a neglected diagnosis. J Fam Pract 1995;41:169-75
6. Polonsky WH. Emotional and quality-of-life aspects of diabetes management. Curr Diab Rep 2002;2:153-9
7. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes. Diabetes Care 2004;27:17-20
8. Patton JS. Deep lung delivery of therapeutic proteins. Chemtech 1997;27:34-8
9. Sayani AP, Chien YW. Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst 1996;13:85-184
10. Hirai S, Yashiki T, Mima H. Mechanisms for the enhancement of insulin. Int J Pharm 1981;9:173-84
11. Patton JS. Mechanisms of macromolecule absorption by the lung. Adv Drug Delivery Rev 1996;19:3-36
12. American Conference of Governmental Industrial Hygienists. Threshold limit values for chemical substances and physical agents and biological exposure indices, 1992-1993. American Conference of Governmental Industrial Hygienists: Cincinnati, OH, 1993, p.29
13. Gänssien M. Uber inhalation von insulin. Klin Wochenschr 1925;4:71
14. White S, Bennett DB, Cheu S, et al. Exubera: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 2005;7:896-906
15. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986;75:433-8
16. Aradigm. 2002 Annual Report. Available from http://www. aradigm.com/ar2002/Aradigm2002AR.pdf [Last accessed 1 Feb 2006]
17. DrugResearcher.com. Pulmonary insulin delivery - which products will triumph? Available from http://www. drugresearcher.com/news/ng.asp?n=65362-novo- nordisk-elililly-insulin-pulmonary-exubera [Last accessed 1 Feb 2006]
18. Pfizer Inc. Pfizer receives FDA approval for Exubera, the first inhalable form of insulin for controlling type 1 and type 2 diabetes in adults. Available from http://mediaroom.pfizer. com/index.php?s=press_releases&item=30 [Last accessed 21 Jul 2006]
19. Alkermes Inc. Phase 2 study shows Lilly/Alkermes inhaled insulin system achieved blood sugar levels similar to injected insulin. Available from http://www.alkermes.com/newsroom/showArticle.aspx?id=335 [Last accessed 1 Feb 2006]
20. MannKind Corporation. MannKind initiates US pivotal phase 3 study of inhaled Technosphere® insulin. Available from http://phx.corporate-ir.net/ phoenix.zhtml?c=147953&p=irol-newsAr ticle&ID=724910&highlight= [Last accessed 1 Feb 2006]
21. Kos Pharmaceuticals. Kos reports achievement of new research and development milestones. Available from http://www. kospharm.com/files/8262004. pdf [Last accessed 20 Jul 2006]
22. Patton JS. Pulmonary drug delivery comes of age: the outlook for 2005 and beyond. Drug Delivery Technology 2005;5:45-9
23. Hermansen K, Ronnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27:162
24. Farr SJ, McElduff A, Mather LE, et al. Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2000;2:185-97
25. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004;43:781-801
26. Exubera® [US package insert]. New York, NY. Pfizer Labs, a division of Pfizer Inc; 2006
27. Rave KM, Nosek L, De La Pena A, et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005;28:2400-5
28. Valente AXCN, Langer R, Stone HA, et al. Recent advances in the development of an inhaled insulin product. Biodrugs 2003;17:9-17
29. Pfützner A, Mann AE, Steiner SS. Technosphere™/insulin - a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002;4:589-94
30. Steiner S, Pfützner A, Wilson BR, et al. Technosphere/insulin - proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002;110:17-21
31. Kapitza C, Heise T, McGovern M, et al. Time-action profile of a new pulmonary insulin applied with a metered-dose inhaler. Diabetes 2003;52(Suppl 1):A105
32. MedGadget. Internet Journal of Emerging Medical Technologies. Technosphere® insulin enters into phase 3 safety trial. Available from http://www.medgadget.com/archives/2005/06/technosphere_in.html [Last accessed 10 Feb 2006]
33. DeLong M, Wright J, Dawson M, et al. Dose delivery of the AIR® pulmonary delivery system over a range of inspiratory flow rates. J Aerosol Med 2005;18:452-9
34. Heinemann L, Heise T, Wahl LC, et al. Prandial glycemia after a carbohydrate-rich meal in type 1 diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabetic Medicine 1996;13:635-9
35. Heinemann L, Heise T. Current status of the development of inhaled insulin. Br J Diabetes Vase Dis 2004;4:295-301
36. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28:1077-82
37. Gelfand RA, Schwartz S, Horton M. Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes (NIDDM). Diabetes 1998;47 (Suppl 1):A99
38. Cefalu WT, Skyler JS, Kourides IA, et al., for the Inhaled Insulin Study Group. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Int Med 2001;134:203-7
39. Steiner S, Pfützner A, Wilson BR, et al. Technosphere/insulin - proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002;110:17-21
40. Quattrin T, Bélanger A, Bohannon NJV, et al., for the Exubera Phase 3 Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care 2004;27:2622-7
41. Skyler JS, Weinstock RS, Raskin P, et al., for the Inhaled Insulin Phase 3 Type 1 Study Group. Use of inhaled insulin in a basal/bolus regimen in type 1 diabetic subjects. Diabetes Care 2005;28:1630-5
42. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 2004;27:2356-62
43. DeFronzo RA, Bergenstal RM, Cefalu WT, et al., for the Exubera Phase 3 Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care 2005;28:1922-8
44. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin (Exubera®) improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized controlled trial. Ann Intern Med 2005;143:549-58